Replies to post #4656 on InMed Pharmaceuticals Inc (INM)

[aparatchik]

I’m hoping for ADR’s on NASDAQ, not a Canadian uplist.

Why: GW pharma currently has a $3.5B market cap on revenue of approximately $10-12M annual and have been burning cash heavily. Even more interesting, at this point 80+% of GW’s share are institutionally owned.

Considering Inmed has significant diversification advantages in revenue pipelines, it’s not difficult to see how they’re well positioned for a sharp uptick based on positive news on a multitude of vectors. I also believe it can absorb a reasonable (not a catastrophic) disappointment in any of their potential rev buckets without being completely derailed.

At a share price under $2, a market cap of $230M and trading on the OTC, Inmed still below the radar for US institutional investors. For a variety of reasons they can’t/won’t touch it yet... enabling them is a key to unlocking exponential sharecorice growth.

[lesgetrich]

Question: with inmed listed on different stock exchanges, does the volume and pps on one translate to another?

Short answer is yes. US shares are actually American Depository Receipts (ADR's) that entitle the bearer to one Canadian Share. Since the US and Canadian markets trade separately, they can diverge from simple currency exchange rate equivalence. However, both market forces and Market Makers keep them relatively balanced most of the time. When there's a big divergence from currency exchange rates between the two markets, shareholders can get clues on the direction their shares will be going.

An uplist from either exchange doesn't by itself affect the share price. The uplist by itself is price neutral unless it's accompanied by a stock split or reverse split. It's what happens afterwards with potential institutional investment and the psychological impact of the uplist that affects the price on both markets.

Volume is not controlled but volume in one market, particularly volume spikes, can have a psychological effect on the other market.

Hope that helps.